__smbhome.uscs.susx.ac.uk_tjk30_Documents_jamaneurology_howard_2019_oi_190089.pdf (438.35 kB)
Minocycline at 2 different dosages vs placebo for patients with mild alzheimer disease
journal contribution
posted on 2023-06-09, 19:51 authored by Robert Howard, Olga Zubko, Rosie Bradley, Emma Harper, Lynn Pank, John O'Brien, Chris Fox, Naji TabetNaji Tabet, Gill Livingston, Peter Bentham, Rupert McShane, Alistair Burns, Craig Richie, Suzzane Reeves, Simon Lovestone, Clive Ballard, Wendy Noble, Ramin Nilforooshan, Gordon Wilcock, Richard GrayImportance - There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of ß-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. Objective - To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD. Design, Setting, and Participants Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 886 screened patients, 554 patients with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score =24) were randomized. Interventions - Participants were randomly allocated 1:1:1 in a semifactorial design to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months. Main Outcomes and Measures - Primary outcome measures were decrease in sMMSE score and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat repeated-measures regression. Results - Of 544 eligible participants (241 women and 303 men), the mean (SD) age was 74.3 (8.2) years, and the mean (SD) sMMSE score was 26.4 (1.9). Fewer participants completed 400-mg minocycline hydrochloride treatment (28.8% [53 of 184]) than 200-mg minocycline treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P?
History
Publication status
- Published
File Version
- Published version
Journal
JAMA NeurologyISSN
2168-6149Publisher
American Medical AssociationExternal DOI
Issue
2Volume
77Page range
164-174Department affiliated with
- BSMS Neuroscience Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2019-12-04First Open Access (FOA) Date
2019-12-04First Compliant Deposit (FCD) Date
2019-12-03Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC